Construction of anti-CD20 single-chain antibody-CD28-CD137-TCRζ recombinant genetic modified T cells and its treatment effect on B cell lymphoma

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 2110-2115

  Chen, Fei ^a   Fan, Chuming ^b   Gu, Xuezhong ^a   Zhang, Haixi ^a   Liu, Qian ^a   Gao, Xiaoli ^a   Lu, Jie ^a   He, Baoli ^c   Lai, Xun ^a  

^a The First People's Hospital of Yunnan Province   (China)

^b People's Hospital of Yunnan Province   (China)

^c KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

CD4 positive T lymphocytes; Human T lymphotropic virus 1; Sleep arousal disorders

Indexed keywords

GREEN FLUORESCENT PROTEIN; LACTATE DEHYDROGENASE; LENTIVIRUS VECTOR; ANTIGEN T CELL RECEPTOR, ZETA CHAIN; CD137 ANTIGEN; CD20 ANTIGEN; CD28 ANTIGEN; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ANIMAL MODEL; ANTI CD20 CD28 CD137 TCRZ FUSION GENE; ARTICLE; B CELL LYMPHOMA; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA MODIFICATION; FLUORESCENCE MICROSCOPY; FUSION GENE; GENE SEQUENCE; GENE THERAPY; GENETIC RECOMBINATION; GENETIC TRANSFECTION; IMMUNOTHERAPY; LYMPH NODE BIOPSY; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN EXPRESSION; RECOMBINANT PLASMID; SURVIVAL RATE; T LYMPHOCYTE; TUMOR VOLUME; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CD4+ T LYMPHOCYTE; GENE FUSION; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; LYMPHOMA, B-CELL; NUDE MOUSE; PROCEDURES; RANDOMIZATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD20; ANTIGENS, CD28; CD4-POSITIVE T-LYMPHOCYTES; GENE FUSION; HEK293 CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, B-CELL; MICE; MICE, NUDE; RANDOM ALLOCATION; RECEPTORS, ANTIGEN, T-CELL; RECOMBINATION, GENETIC; SINGLE-CHAIN ANTIBODIES; TRANSFECTION;

EID: 84937920235     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.893791     Document Type: Article

References (25)

1. Czuczman MS, Grillo-Lopez AJ, White CA et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol, 1999; 17: 268–76
2. Motta G, Cea M, Carbone F et al: Current standards and future strategies in immunochemotherapy of non-Hodgkin’s lymphoma. J BUON, 2011; 16: 9–15
3. Steinebrunner N, Sandig C, Sommerer C et al: Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes –a prospective study. Ann Transplant, 2014; 19: 32–40
4. Brody J, Kohrt H, Marabelle A, Levy R: Active and passive immunotherapy for lymphoma: proving principles and improving results. J Clin Oncol, 2011; 29: 1864–75
5. Kuroki M, Shirasu N: Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens. Anticancer Res, 2014; 34: 4481–88
6. Zang YW, Gu XD, Xiang JB, Chen ZY: Clinical application of adoptive T cell therapy in solid tumors. Med Sci Monit, 2014; 20: 953–59
7. Hainsworth JD, Spigel DR, Markus TM et al: Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma, 2009; 9: 223–28
8. Sadelain M, Riviere I, Brentjens R: Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer, 2003; 3: 35–45
9. Harris NL, Jaffe ES, Stein H et al: Lymphoma classification proposal: clarification. Blood, 1995; 85: 857–60
10. Anderson KC, Bates MP, Slaughenhoupt BL et al: Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood, 1984; 63: 1424–33
11. Milone MC, Fish JD, Carpenito C et al: Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther, 2009; 17: 1453–64
12. Wilcox RA, Tamada K, Strome SE, Chen L: Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol, 2002; 169: 4230–36
13. Agliano A, Martin-Padura I, Marighetti P et al: Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res, 2011; 17: 6163–73
14. Cheson BD, Leonard JP: Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med, 2008; 359: 613–26
15. Khouri IF, Saliba RM, Erwin WD et al: Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood, 2012; 119: 6373–78
16. Bacher U, Klyuchnikov E, Le-Rademacher J et al: Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood, 2012; 120: 4256–62
17. Wang J, Press OW, Lindgren CG et al: Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther, 2004; 9: 577–86
18. Kowolik CM, Topp MS, Gonzalez S et al: CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res, 2006; 66: 10995–1004
19. Yeung MY, Najafian N, Sayegh MH: Targeting CD28 to prevent transplant rejection. Expert Opin Ther Targets, 2014; 18: 225–42
20. Leung J, Suh WK: The CD28-B7 family in anti-tumor immunity: emerging concepts in cancer immunotherapy. Immune Netw, 2014; 14: 265–76
21. Lin CH, Hunig T: Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol, 2003; 33: 626–38
22. Gerdes N, Zirlik A: Co-stimulatory molecules in and beyond co-stimulation– tipping the balance in atherosclerosis? Thromb Haemost, 2011; 106: 804–13
23. Nozawa K, Ohata J, Sakurai J et al: Preferential blockade of CD8(+) T cell responses by administration of anti-CD137 ligand monoclonal antibody results in differential effect on development of murine acute and chronic graft-versus-host diseases. J Immunol, 2001; 167: 4981–86
24. Morgan RA, Kakarla S: Genetic modification of T cells. Cancer J, 2014; 20: 145–50
25. Durand S, Cimarelli A: The inside out of lentiviral vectors. Viruses, 2011; 3: 132–59